Home › Geographic Atrophy › North Carolina › Raleigh
Geographic Atrophy clinical trials in Raleigh, NC
4 studies for Geographic Atrophy are looking for participants at sites in and around Raleigh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RecruitingPhase 2/3
- NC Retina Associates, Wake Forest · 16 mi away
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
RecruitingPhase 1/2
- North Carolina (Nc) Retina Associates - Wake Forest Office- Site Number : 8400059, Wake Forest · 16 mi away
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RecruitingPhase 3
- North Carolina Retina Associates, Wake Forest · 16 mi away
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
RecruitingPhase 2
- North Carolina Retina Associates, S.C., Wake Forest · 16 mi away
Geographic Atrophy trials in other cities
- Reno, NV8 studies
- Dallas, TX8 studies
- Austin, TX7 studies
- Santa Monica, CA7 studies
- Naperville, IL6 studies
- Cleveland, OH6 studies
- The Woodlands, TX6 studies
- Baltimore, MD6 studies
- Houston, TX6 studies
- St. Louis, MO5 studies
- Washington, DC5 studies
- San Antonio, TX5 studies
Other studies in Raleigh
- Heart Failure7 studies
- Coronary Artery Disease6 studies
- Obesity6 studies
- Type 2 Diabetes6 studies
- Macular Degeneration6 studies
- Atherosclerosis5 studies
- Overweight5 studies
- Cardiovascular Disease5 studies
- Endometrial Cancer5 studies
- Stroke5 studies
- Kidney Failure4 studies
- Diabetes4 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.